Advances in Peritoneal Dialysis

  Previous Article | Back to Volume | Next Article
  Abstract | References | Citation | Download | Preview | Statistics
Sample volume 1
Title GDPs and AGEs: Impact on Cardiovascular Toxicity in Dialysis Patients
Author Rainer Himmele, Dixie - Ann Sawin, Jose A. Diaz - Buxo
Abstract
Glucose degradation products (GDPs) are highly reactive precursors of advanced glycation end-products (AGEs). High glucose concentrations, GDPs, and AGEs can activate specific pathways, including inflammatory and oxidative stress response pathways, which may adversely affect the cardiovascular system. This review discusses the impact and possible mechanisms of action of GDPs and AGEs with regard to cardiovascular toxicity in chronic kidney disease patients. The AGE–RAGE pathway appears to be particularly important in the pathogenesis of cardiovascular diseases in dialysis patients. In the absence of definitive proof from randomized controlled trials, mounting evidence suggests that high levels of GDPs and AGEs play a role in the pathophysiology of cardiotoxicity.
Citation
References
1 Wieslander A, Forsbäck G, Svensson E, Lindén T. 
Cytotoxicity, pH, and glucose degradation products 
in four different brands of PD fluid. Adv Perit Dial 
1996;12:57–60.
2 Williams JD, Craig KJ, von Ruhland C, Topley N, 
Williams GT, on behalf of the Biopsy Registry Study 
Group. The natural course of peritoneal membrane 
biology during peritoneal dialysis. Kidney Int Suppl 
2003;(88):S43–9.
3 Honda K, Nitta K, Horita S, Yumura W, Nihei H. 
Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. 
Nephron 1996;72:171–6.
4 Nakayama M, Kawaguchi Y, Yamada K, et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible 
pathophysiological role in CAPD. Kidney Int 
1997;51:182–6.
5 Krediet RT, Zweers MM, van der Wal AC, Struijk 
DG. Neoangiogenesis in the peritoneal membrane. 
Perit Dial Int 2000;20(suppl 2):S19–25.
6 Ikehara O, Nishimura H, Naito T, Higuchi C, Sanaka 
T. Effects of neutral pH and reduced glucose degradation products in a new peritoneal dialysis solution on 
morphology of peritoneal membrane in rats. Nephron 
Exp Nephrol 2005;100:e30–9.
7 Mortier S, Faict D, Schalkwijk CG, Lameire 
NH, De Vriese AS. Long-term exposure to new 
peritoneal dialysis solutions: effects on the peritoneal 
membrane. Kidney Int 2004;66:1257–65.
8 Miyata T, Kurokawa K. Carbonyl stress: increased 
carbonyl modification of proteins by autoxidation 
products of carbohydrates and lipids in uremia. Int J 
Artif Organs 1999;22:195–8.
9 Calcutt NA, Cooper ME, Kern TS, Schmidt AM. 
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat 
Rev Drug Discov 2009;8:417–29.
10 Welten AG, Schalkwijk CG, ter Wee PM, Meijer 
S, van den Born J, Beelen RJ. Single exposure of 
mesothelial cells to glucose degradation products 
(GDPs) yields early advanced glycation end-products 
(AGEs) and a proinflammatory response. Perit Dial 
Int 2003;23:213–21.
11 Potenza MA, Gagliardi S, Nacci C, Carratù MR, 
Montagnani M. Endothelial dysfunction in diabetes: 
from mechanisms to therapeutic targets. Curr Med 
Chem 2009;16:94–112.
12 Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin
Invest 2001;108:949–55.
13 Erixon M, Lindén T, Kjellstrand P, et al. PD fluids 
contain high concentrations of cytotoxic GDPs directly after sterilization. Perit Dial Int 2004;24:392–8.
14 Linden T, Cohen A, Deppisch R, Kjellstrand P, 
Wieslander A. 3,4-Dideoxyglucosone-3-ene (3,4-
DGE): a cytotoxic glucose degradation product 
in fluids for peritoneal dialysis. Kidney Int 
2002;62:697–703.
15 Martinson E, Wieslander A, Kjellstrand P, Boberg U. 
Toxicity of heat sterilized peritoneal dialysis fluids 
is derived from degradation of glucose. ASAIO J 
1992;38:M370–2.
16 Coles G. Biocompatibility and new fluids. Perit Dial 
Int 1999;19(suppl 2):S267–70.
17 Igaki N, Sakai M, Hata H, Oimomi M, Baba S, Kato 
H. Effects of 3-deoxyglucosone on the Maillard reaction. Clin Chem 1990;36:631–4.
18 Rippe B, Simonsen O, Heimbürger O, et al. Longterm clinical effects of a peritoneal dialysis fluid 
with less glucose degradation products. Kidney Int 
2001;59:348–57.
19 Zeier M, Schwenger V, Deppisch R, et al. Glucose 
degradation products in PD fluids: do they disappear 
from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003;63:298–305.
20 Chaudhary K, Khanna R. Biocompatible peritoneal 
dialysis solutions: do we have one? Clin J Am Soc 
Nephrol 2010;5:723–32.
21 Williams JD, Topley N, Craig KJ, et al. The EuroBalance Trial: the effect of a new biocompatible 
peritoneal dialysis fluid (Balance) on the peritoneal 
membrane. Kidney Int 2004;66:408–18.
22 Koyama H, Nishizawa Y. AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD? Eur 
J Clin Invest 2010;40:623–35.
23 Krediet RT, Balafa O. Cardiovascular risk in 
the peritoneal dialysis patient. Nat Rev Nephrol 
2010;6:451–60.
24 Müller–Krebs S, Kihm LP, Zeier B, et al. Glucose 
degradation products result in cardiovascular toxicity in a rat model of renal failure. Perit Dial Int 
2010;30:35–40.
25 Makita Z, Radoff S, Rayfield EJ, et al. Advanced 
glycosylation end products in patients with diabetic 
nephropathy. N Engl J Med 1991;325:836–42.
26 Baidoshvili A, Krijnen PA, Kupreishvili K, et al. Nε
-
(carboxymethyl)lysine depositions in intramyocardial 
blood vessels in human and rat acute myocardial 
infarction: a predictor or reflection of infarction? Arterioscler Thromb Vasc Biol 2006;26:2497–503.
27 Miyata T, Inagi R, Asahi K, et al. Generation of protein carbonyls by glycoxidation and lipoxidation reactions with autoxidation products of ascorbic acid and 
polyunsaturated fatty acid. FEBS Lett 1998;437:24–8.
28 Wolffenbuttel BH, Boulanger CM, Crijns FR, et al.
Breakers of advanced glycation end products restore 
large artery properties in experimental diabetes. Proc 
Natl Acad Sci U S A 1998;95:4630–4.
29 Kislinger T, Fu C, Huber B, et al. Nε
-(carboxymethyl)
lysine adducts of proteins are ligands for receptor for 
advanced glycation end products that activate cell 
signaling pathways and modulate gene expression. J 
Biol Chem 1999;274:31740–9.
30 Hofmann MA, Drury S, Fu C, et al. RAGE mediates 
a novel proinflammatory axis: a central cell surface 
receptor for S100/calgranulin polypeptides. Cell 
1999;97:889–901.
31 Park L, Raman KG, Lee KJ, et al. Suppression of 
accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 
1998;4:1025–31.
32 Wendt TM, Tanji N, Guo J, et al. RAGE drives the 
development of glomerulosclerosis and implicates 
podocyte activation in the pathogenesis of diabetic 
nephropathy. Am J Pathol 2003;162:1123–37.
33 Sakaguchi T, Yan SF, Yan SD, et al. Arterial restenosis: central role of RAGE-dependent neointimal 
expansion. J Clin Invest 2003;111:959–72.
34 Cataldegirmen G, Zeng S, Feirt N, et al. RAGE limits 
regeneration after massive liver injury by coordinated suppression of TNF-α and NF-κB. J Exp Med 
2005;201:473–84.
35 Tsoporis JN, Marks A, Kahn HJ, et al. Inhibition of 
norepinephrine-induced cardiac hypertrophy in S100β 
transgenic mice. J Clin Invest 1998;102:1609–16.
36 Bucciarelli LG, Kaneko M, Ananthakrishnan R, et al. 
Receptor for advanced-glycation end products: key 
modulator of myocardial ischemic injury. Circulation 
2006;113:1226–34.
37 Semba RD, Bandinelli S, Sun K, Guralnik JM, Ferrucci L. Plasma carboxymethyl-lysine, an advanced 
glycation end product, and all-cause and cardiovascular disease mortality in older community-dwelling 
adults. J Am Geriatr Soc 2009;57:1874–80.
38 Ateshkadi A, Johnson CA, Founds HW, Zimmerman 
SW. Serum advanced glycosylation end-products in 
patients on hemodialysis and CAPD. Perit Dial Int 
1995;15:129–33.
39 Meerwaldt R, Graaff R, Oomen PH, et al. Simple noninvasive assessment of advanced glycation endproduct 
accumulation. Diabetologia 2004;47:1324–30.
40 Meerwaldt R, Hartog JW, Graaff R, et al. Skin autofluorescence, a measure of cumulative metabolic 
stress and advanced glycation end products, predicts 
mortality in hemodialysis patients. J Am Soc Nephrol 
2005;16:3687–93.
41 Tanaka K, Katoh T, Asai J, et al. Relationship of 
skin autofluorescence to cardiovascular disease in 
Japanese hemodialysis patients. Ther Apher Dial 
2010;14:334–40.
42 Nagano M, Fukami K, Yamagishi S, et al. Tissue 
level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive 
protein levels in haemodialysis patients. Nephrology 
(Carlton) 2011;16:299–303.
Keywords Advanced glycation end-products, glucose degradation products, cardiotoxicity, cardiovascular toxicity, chronic kidney disease
Download Full PDF Download
  Previous Article | Back to Volume | Next Article
Share
Search in articles
Statistics
Journal Published articles
APD 49
Journal Hits
APD 164421
Journal Downloads
APD 165
Total users online -